Gastric Cancer Therapy Market Growth Is Accelerating As Industry Transformation Continues
Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Gastric Cancer Therapy Market Size And Revenue Forecast Through 2030
The gastric cancer treatment market has experienced robust expansion over recent years. Valued at $4.5 billion in 2025, it is projected to reach $4.92 billion by 2026, reflecting a compound annual growth rate (CAGR) of 9.3%. This historical growth has been driven by factors such as the scarcity of targeted therapies, a heavy dependence on traditional chemotherapy and surgical interventions, a rising incidence of gastric cancer, the ongoing development of oncology facilities in hospitals, and heightened awareness surrounding early detection initiatives.
The gastric cancer therapy market is anticipated to experience substantial growth in the coming years, with its value projected to reach $6.96 billion by 2030, expanding at a compound annual growth rate (CAGR) of 9.1%. This forecasted growth is driven by factors such as the development of novel immunotherapies and checkpoint inhibitors, a rising focus on precision medicine, the expansion of outpatient oncology services, increased funding for gastric cancer research, and the integration of digital health tools for patient monitoring. Key trends shaping this period include a growing emphasis on targeted and personalized therapies, the increasing use of combination treatment strategies, the expansion of early detection and screening initiatives, broader availability of home care and ambulatory treatment options, and a heightened focus on reducing side effects while enhancing patient quality of life.
Download A Free Sample Report For Comprehensive Market Insights:
Gastric Cancer Therapy Market Expansion Drivers: What Is Shaping Future Growth?
The growing incidence of helicobacter pylori infection is anticipated to drive expansion in the gastric cancer therapy market moving forward. As a bacterial infection primarily impacting the stomach lining, helicobacter pylori is a major contributor to chronic gastritis and gastric cancer. Its prevalence is on the rise mainly due to poor sanitation, where inadequate hygiene and contaminated food or water enable its transmission through oral-oral or fecal-oral routes. Gastric cancer therapy is employed to lower the risk of stomach cancer linked to this infection by addressing the infection itself, reducing gastric inflammation and cellular harm, and halting the development of chronic gastritis and atrophic changes that may result in malignant transformation of the stomach lining. A November 2024 report from the Government of Canada, a federal administration based in Canada, indicated that as of January 2023, the recurrence rate of H. pylori infection can reach as high as 19%, though this figure varies by geographic area and age group. Consequently, the increasing prevalence of helicobacter pylori infection is fueling growth in the gastric cancer therapy market.
Gastric Cancer Therapy Market Segment Landscape: Which Areas Lead Market Development?
The gastric cancer therapy market covered in this report is segmented –
1) By Therapy Type: Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Surgery
2) By Drug Class: Cytotoxic Agents, Monoclonal Antibodies, Tyrosine Kinase Inhibitors, Checkpoint Inhibitors, Miscellaneous Agents
3) By Administration Route: Oral, Intravenous, Intramuscular, Subcutaneous
4) By Stage of Disease: Early Stage, Locally Advanced Stage, Metastatic Stage
5) By End User: Hospitals, Oncology Clinics, Ambulatory Surgical Centers, Research Institutions, Home Care Settings
Subsegments:
1) By Chemotherapy: Neoadjuvant Chemotherapy (NAC), Adjuvant Chemotherapy (AC), Palliative Chemotherapy (PC), Combination Chemotherapy, Monotherapy
2) By Targeted Therapy: Human Epidermal Growth Factor Receptor 2 (HER2) Targeted Therapy, Vascular Endothelial Growth Factor (VEGF) Inhibitors, Fibroblast Growth Factor Receptor (FGFR) Inhibitors, Mesenchymal-Epithelial Transition (MET) Inhibitors, Claudin 18 Isoform 2 Inhibitors
3) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines, Adoptive Cell Transfer, Cytokine Therapy, Combination Immunotherapy
4) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Intensity-Modulated Radiation Therapy (IMRT), Three-Dimensional Conformal Radiation Therapy (3D-CRT), Brachytherapy
5) By Surgery: Endoscopic Mucosal Resection (EMR), Endoscopic Submucosal Dissection (ESD), Subtotal Gastrectomy, Total Gastrectomy, Lymphadenectomy
Gastric Cancer Therapy Market Strategic Trends: What Is Defining The Next Phase Of Growth?
Major players in the gastric cancer therapy market are concentrating on the creation of novel treatments, particularly combination therapies, aimed at boosting treatment effectiveness and enhancing patient results. Combination therapy refers to the simultaneous application of multiple treatment modalities—such as chemotherapy, targeted therapy, or immunotherapy—to amplify overall efficacy. A notable example occurred in December 2024, when BeOne Medicines Ltd., a Chinese pharmaceutical firm previously called BeiGene, secured U.S. Food and Drug Administration (FDA) approval for Tevimbra (tislelizumab-jsgr) paired with platinum- and fluoropyrimidine-based chemotherapy. This regimen is indicated for the first-line management of adults suffering from unresectable or metastatic HER2-negative gastric or gastroesophageal junction (G/GEJ) adenocarcinoma where tumor PD-L1 expression is at least 1%. The approval was grounded in findings from the Phase 3 RATIONALE-305 trial, which revealed that the combined treatment extended median overall survival to 15.0 months, versus 12.9 months with chemotherapy alone, thereby cutting the risk of death by 20%. This achievement underscores an escalating focus among leading pharmaceutical entities on investing in advanced, multimodal therapeutic strategies that merge immunotherapy with standard chemotherapy approaches to elevate clinical results, slow disease advancement, and boost survival prospects for individuals facing advanced gastric cancer.
Gastric Cancer Therapy Market Industry Leaders And Market Competition
Major companies operating in the gastric cancer therapy market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Eli Lilly and Company, Amgen Inc., Astellas Pharma Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., BeiGene Ltd., Celltrion Healthcare Co. Ltd., Hutchison MediPharma Limited, Shanghai Henlius Biotech Inc.
Access The Complete Gastric Cancer Therapy Market Report:
Gastric Cancer Therapy Market Largest Region: Which Geography Holds The Highest Market Share?
North America was the largest region in the gastric cancer therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastric cancer therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
